Global Advances in Hepatocellular Carcinoma Research and Therapy in 2025

Hepatocellular carcinoma (HCC) remains a significant global health burden, characterized by high mortality and evolving etiological patterns marked by a rise in metabolic dysfunction-associated cases. Over the past year, the therapeutic landscape has substantially evolved, driven by the maturity of clinical data regarding novel diagnostic and treatment strategies. This review synthesizes the milestone breakthroughs achieved through 2025 to provide an updated framework for the multidisciplinary management of this complex malignancy. Advances in early diagnosis have been propelled by the integration of artificial intelligence with imaging and the refinement of liquid biopsy biomarkers, significantly enhancing detection accuracy. Moreover, new findings on tumor microenvironment spatial ecosystem, metabolic reprogramming, and gut-liver axis are revealing new targets that shape these changing therapeutic modalities. Nowadays, in the clinical environment, the enhancement of resectability still gains momentum with novel conversion protocols and the least invasive approaches. One of the most notable changes is the latest development in perioperative care wherein combined systemic and locoregional interventions, such as combinations of immune checkpoint inhibitors and tyrosine kinase inhibitors, have attained previously unachieved pathological response and effectively decreased postoperative recurrence in high-risk patients. In case of progressive disease, advances in treatment models of choice have put a strong emphasis on using combination systems of regimens, which have proven better survival advantages than conventional monotherapies. All these developments highlight the shift from mono-modality therapies to more complex and individualized combination approaches, which imply that comprehensive multimodal interventions will become a standard of care and enhance patient outcomes in the long term among patients with HCC.